- Home
- GTHX
GTHX
G1 Therapeutics Inc.
as 07-08-2024 4:00pm EST
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | N/A | IPO Year: | 2017 |
| Target Price: | $8.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.08 - $6.14 | Next Earning Date: | 07-31-2024 |
| Revenue: | $84,041,000 | Revenue Growth: | 46.55% |
| Revenue Growth (this year): | -10.67% | Revenue Growth (next year): | 36.91% |
Stock Insider Trading Activity of G1 Therapeutics Inc. (GTHX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Thomas Monica R. | GTHX | Chief Legal & People Officer | May 23 '24 | Sell | $4.27 | 5,826 | $24,864.20 | 109,825 | SEC Form 4 |
| Umstead John W. V | GTHX | Chief Financial Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 153,245 | SEC Form 4 |
| Avagliano Mark | GTHX | Chief Business Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 209,683 | SEC Form 4 |
| Malik Rajesh | GTHX | Chief Medical Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 161,787 | SEC Form 4 |
| MURDOCK TERRY L | GTHX | Chief Operating Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 95,487 | SEC Form 4 |
| Perry Andrew | GTHX | Chief Commercial Officer | May 13 '24 | Sell | $4.79 | 8,151 | $39,033.51 | 78,951 | SEC Form 4 |
| Bailey John E. (Jack) Jr. | GTHX | President and CEO | May 13 '24 | Sell | $4.79 | 37,258 | $178,421.11 | 452,336 | SEC Form 4 |
| Umstead John W. V | GTHX | Chief Financial Officer | Mar 18 '24 | Sell | $3.02 | 6,547 | $19,751.64 | 123,896 | SEC Form 4 |
| Malik Rajesh | GTHX | Chief Medical Officer | Feb 12 '24 | Sell | $4.62 | 28,600 | $132,143.44 | 169,938 | SEC Form 4 |
| Avagliano Mark | GTHX | Chief Business Officer | Jan 3 '24 | Sell | $2.94 | 721 | $2,121.40 | 117,834 | SEC Form 4 |
| Avagliano Mark | GTHX | Chief Business Officer | Jan 3 '24 | Sell | $3.12 | 2,602 | $8,115.38 | 118,555 | SEC Form 4 |
| Avagliano Mark | GTHX | Chief Business Officer | Jan 3 '24 | Sell | $3.12 | 758 | $2,364.13 | 121,157 | SEC Form 4 |
| Umstead John W. V | GTHX | Chief Financial Officer | Jan 3 '24 | Sell | $2.94 | 111 | $326.60 | 130,443 | SEC Form 4 |
| Umstead John W. V | GTHX | Chief Financial Officer | Jan 3 '24 | Sell | $3.12 | 379 | $1,182.06 | 130,554 | SEC Form 4 |
| Umstead John W. V | GTHX | Chief Financial Officer | Jan 3 '24 | Sell | $3.12 | 253 | $789.08 | 130,933 | SEC Form 4 |
| Perry Andrew | GTHX | Chief Commercial Officer | Jan 3 '24 | Sell | $3.12 | 379 | $1,182.06 | 89,136 | SEC Form 4 |
| Perry Andrew | GTHX | Chief Commercial Officer | Jan 3 '24 | Sell | $3.12 | 2,034 | $6,343.84 | 87,102 | SEC Form 4 |
| Malik Rajesh | GTHX | Chief Medical Officer | Jan 3 '24 | Sell | $3.12 | 758 | $2,364.13 | 172,920 | SEC Form 4 |
| Malik Rajesh | GTHX | Chief Medical Officer | Jan 3 '24 | Sell | $3.12 | 2,261 | $7,051.83 | 170,659 | SEC Form 4 |
| Malik Rajesh | GTHX | Chief Medical Officer | Jan 3 '24 | Sell | $2.94 | 721 | $2,121.40 | 169,938 | SEC Form 4 |
| Bailey John E. (Jack) Jr. | GTHX | President and CEO | Jan 3 '24 | Sell | $3.12 | 2,592 | $8,084.19 | 498,688 | SEC Form 4 |
| Bailey John E. (Jack) Jr. | GTHX | President and CEO | Jan 3 '24 | Sell | $3.12 | 9,094 | $28,363.28 | 489,594 | SEC Form 4 |
| Bailey John E. (Jack) Jr. | GTHX | President and CEO | Jan 2 '24 | Sell | $3.27 | 32,983 | $108,006.13 | 400,580 | SEC Form 4 |
| Malik Rajesh | GTHX | Chief Medical Officer | Dec 11 '23 | Sell | $3.06 | 21,439 | $65,659.08 | 136,378 | SEC Form 4 |
| Malik Rajesh | GTHX | Chief Medical Officer | Dec 11 '23 | Sell | $4.02 | 12,400 | $49,862.88 | 136,378 | SEC Form 4 |
Latest G1 Therapeutics Inc. News
GTHX Breaking Stock News: Dive into GTHX Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
G1 Therapeutics Joins Russell 3000, Russell 2000 Indexes
GlobeNewswire
7 days ago
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
Clinical Trials Arena
14 days ago
G1 Therapeutics discontinue COSELA in TNBC following Phase III flop
MT Newswires
14 days ago
Top Midday Decliners
MT Newswires
14 days ago
Top Premarket Decliners
MT Newswires
14 days ago
G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints
GlobeNewswire
15 days ago
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
Simply Wall St.
a month ago
It's Probably Less Likely That G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Will See A Huge Pay Rise This Year
Share on Social Networks:
Disclaimer
The information presented on this page, "GTHX G1 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.